



**FOR IMMEDIATE RELEASE**

## **Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance**

**Cambridge, MA – April 5, 2010.** Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for cancer and autoimmune disease, today announced that William Sullivan has been promoted to Vice President of Finance.

“Bill has led Merrimack’s finance and accounting efforts and played a vital role in both our acquisition of Hermes Biosciences and the completion of our partnership with sanofi-aventis,” said Robert Mulroy, President and Chief Executive Officer of Merrimack Pharmaceuticals. “His past experience coupled with the work he has done at Merrimack gives our leadership team and Board of Directors full confidence that Bill is the right choice to successfully direct the company’s financial strategy.”

In his new position, Mr. Sullivan, will continue to lead Merrimack’s finance department to ensure the Company is prepared for growth and future financings. In addition to his previous role, Mr. Sullivan now has full responsibility for the company’s daily financial and legal operations.

Prior to joining Merrimack, Mr. Sullivan comes from a diverse career which includes establishing and managing finance departments and working in public and private corporate accounting. He holds a Bachelor’s degree from Williams College, a Master’s degree in Business Administration (MBA) and a Master’s degree in Accounting from Northeastern University’s Graduate School of Professional Accounting. In addition, he is a Certified Public Accountant (CPA).

### **About Merrimack**

Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit <http://www.merrimackpharma.com>.

Contact: Kathleen Petrozzelli, Corporate Communications, 617-441-1043,  
[kpetrozzelli@merrimackpharma.com](mailto:kpetrozzelli@merrimackpharma.com)  
Betsy Stevenson, RaymondStevenson Healthcare, 860-984-1424,  
[betsy@raymondstevenson.com](mailto:betsy@raymondstevenson.com)

###